These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 23199501)

  • 1. The role of viral and host genetics in natural history and treatment of chronic HCV infection.
    Doyle JS; Hellard ME; Thompson AJ
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):413-27. PubMed ID: 23199501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection.
    Feld JJ
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):429-44. PubMed ID: 23199502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic variation-guided management in chronic hepatitis C.
    Hsu CS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2012 Aug; 6(4):497-506. PubMed ID: 22928901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin.
    Sadeq R; Mohtady H; Al Badawy N; Ibrahim S; Omar AR; Husseiny MI; El Zowalaty M
    J Infect Dev Ctries; 2013 Nov; 7(11):859-67. PubMed ID: 24240045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
    Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
    J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hepatitis C revolution part 1: antiviral treatment options.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
    European Association of the Study of the Liver
    Liver Int; 2012 Feb; 32 Suppl 1():2-8. PubMed ID: 22212565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral and host factors associated with outcomes of hepatitis C virus infection (Review).
    Yan Z; Wang Y
    Mol Med Rep; 2017 May; 15(5):2909-2924. PubMed ID: 28339063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
    N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
    De Meyer S; Ghys A; Foster GR; Beumont M; Van Baelen B; Lin TI; Dierynck I; Ceulemans H; Picchio G
    J Viral Hepat; 2013 Jun; 20(6):395-403. PubMed ID: 23647956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of chronic hepatitis viral C: new associations].
    Ouzan D
    Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.
    Aziz S
    J Coll Physicians Surg Pak; 2012 Oct; 22(10):615-6. PubMed ID: 23058141
    [No Abstract]   [Full Text] [Related]  

  • 18. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
    Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
    Li LF; Shi KQ; Lin YQ; Wang LR; He JP; Braddock M; Chen YP; Zheng MH
    Gene; 2014 Jul; 544(2):101-6. PubMed ID: 24793583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.